Rethinking obesity counseling: having the French Fry Discussion

Jonathan Bonnet1, Aaron George1, Pippa Evans2

  • 1Department of Community and Family Medicine, Duke University Health System, P.O. Box 104425, Durham, NC 27710, USA.

Journal of Obesity
|November 12, 2014
PubMed

Insights

Pediatricians face barriers to addressing childhood obesity. Many PCPs (primary care providers) delay discussing fast food habits until a child is two years old, missing crucial early intervention opportunities.

Area of Science:

  • Pediatrics
  • Family Medicine
  • Public Health

Background:

  • Childhood obesity requires early intervention, yet current recommendations lack specificity for pediatric populations.
  • Family medicine primary care providers (PCPs) play a key role in obesity prevention and treatment.
  • Understanding PCPs' perceived barriers and practices is crucial for developing targeted strategies.

Purpose of the Study:

  • To examine perceived barriers encountered by PCPs in preventing and treating pediatric obesity.
  • To assess the practice behaviors of PCPs regarding obesity-related counseling during well-child visits.

Main Methods:

  • A written survey was administered to PCPs across eleven family medicine clinics.
  • The survey focused on perceived barriers and current practices related to childhood obesity at well-child visits.

Main Results:

  • The primary barriers identified by PCPs were insufficient family exercise (93%) and frequent fast-food consumption (86%).
  • Most PCPs do not discuss fast food before the 12-month well-child visit.
  • A majority of PCPs (68%) first discuss fast food at the two-year well-child visit.

Conclusions:

  • There is no established consensus on when PCPs should initiate discussions about fast food during early well-child visits.
  • Dietary habits shift significantly towards fast foods between the one- and two-year well-child visits.
  • A "French Fry Discussion" at every 12-month well-child visit is recommended for timely intervention.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
352
Binge Eating Disorders01:23

Binge Eating Disorders

Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
835
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
431
Fats as Energy Storage Molecules01:06

Fats as Energy Storage Molecules

Triglycerides are a form of long-term energy storage molecules. They are made of glycerol and three fatty acids. To obtain energy from fat, triglycerides must first be broken down by hydrolysis into their two principal components, fatty acids and glycerol. This process, called lipolysis, takes place in the cytoplasm. The resulting fatty acids are oxidized by β-oxidation into acetyl-CoA, which is used by the Krebs cycle. The glycerol that is released from triglycerides after lipolysis...
27.6K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
310